Inflammasomes and Atherosclerosis: a Mixed Picture.

Area of Science:

• Cardiovascular Research
• Immunology
• Genetics

Background:

• The CANTOS and colchicine trials highlight the role of inflammasomes and interleukin-1β (IL-1β) in atherosclerotic cardiovascular disease.
• Mouse models suggest a causal link between inflammasomes, IL-1β, and atherosclerosis.
• Recent research provides a more detailed understanding of inflammasome involvement in atherosclerosis.

Purpose of the Study:

• To explore the nuanced role of inflammasomes in atherosclerosis.
• To identify specific conditions that trigger inflammasome activation in cardiovascular disease.
• To support a precision medicine approach for cardiovascular disease treatment.

Main Methods:

• Review of recent studies on inflammasome activation in atherosclerosis.
• Analysis of findings from hyperlipidemic mouse models.
• Examination of human genetic studies linking clonal hematopoiesis to cardiovascular risk.

Main Results:

• NLRP3 inflammasome activation in mice requires secondary triggers like defective cholesterol efflux, DNA repair, clonal hematopoiesis, or diabetes.
• Human mutations associated with clonal hematopoiesis increase coronary artery disease risk partly via inflammasome activation.
• The AIM2 inflammasome is implicated in cardiovascular disease, including in clonal hematopoiesis and diabetes.

Conclusions:

• Inflammasome activation is a critical factor in various cardiovascular disease contexts.
• Specific conditions like clonal hematopoiesis and diabetes enhance inflammasome-driven cardiovascular risk.
• Targeting inflammasomes or IL-1β offers a potential precision medicine strategy for select patient populations.